Resorcinolnaphthalein (Synonyms: NSC 354317) |
| Catalog No.GC11560 |
레조르시놀나프탈레인은 특정 안지오텐신 전환 효소 2(ACE2) 인핸서이며 19.5μM의 EC50 값으로 ACE2 활성을 활성화합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 41307-63-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Resorcinolnaphthalein is an Angiotensin-converting enzyme 2 (ACE2) activator [1].
Angiotensin-converting enzyme 2 (ACE2) has been involved in hydrolyzing angiotensin II and opposing its actions, and plays a protective role in the pathogenesis of pulmonary arterial hypertension (PAH) [2]. Targeted disruption of ACE2 in mice results in a severe cardiac contractility defect, increased angiotensin II levels, and upregulation of hypoxia-induced genes in the heart [2].
In vitro: Resorcinolnaphthalein enhanced ACE2 activity in a dose-dependent manner [1].
In vivo: Resorcinolnaphthalein caused significant activation of ACE2 in both normal and diseased rats in 7 days after treatment. Treatment with resorcinolnaphthalein prevented high PAP, right ventricular hypertrophy and neointimal formation. Resorcinolnaphthalein caused an improved endothelia-dependent vasorelaxation and decreased in proinflammatory cytokines, such as TNF-α, MCp-1, IL-6, and increased in anti-inflammatory cytokine IL-10 in the early stage of the pathogenesis [3]. Resorcinolnaphthalein can specifically and effectively enhanced ACE2 activity in rats [4]. ACE2 activation by resorcinolnaphthalein showed effects on pulmonary endothelial dysfunction and neointimal formation during the development of severe PAH in rats [4].
References:
[1] Prada J A H, Ferreira A J, Katovich M J, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents[J]. Hypertension, 2008, 51(5): 1312-1317.
[2] Crackower M A, Sarao R, Oudit G Y, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function[J]. Nature, 2002, 417(6891): 822-828.
[3] Haber P K, Ye M, Wysocki J, et al. Angiotensin-converting enzyme 2–independent action of presumed angiotensin-converting enzyme 2 activatorsNovelty and significance[J]. Hypertension, 2014, 63(4): 774-782.
[4] Li G, Liu Y, Zhu Y, et al. ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats[J]. Lung, 2013, 191(4): 327-336.
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *